Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY4066708 in Healthy Participants
NCT07046559Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- May 2025
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LY4066708 in cancer, sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Serious Adverse Events (SAEs) Considered by the Investigator to be Related to Study Drug Administration at 12 weeks. Started May 2025; status: recruiting.
02
Drugs
LY4066708
03
Conditions
cancer
Beyond the preview
Go deeper on NCT07046559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07046559.